194 related articles for article (PubMed ID: 22292750)
1. Novel strategies for hepatocellular carcinoma based on MMPs science.
Okazaki I; Inagaki Y
Anticancer Agents Med Chem; 2012 Sep; 12(7):753-63. PubMed ID: 22292750
[TBL] [Abstract][Full Text] [Related]
2. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families.
He XX; Shi LL; Qiu MJ; Li QT; Wang MM; Xiong ZF; Yang SL
Biochem Biophys Res Commun; 2018 Oct; 504(4):878-884. PubMed ID: 30219235
[TBL] [Abstract][Full Text] [Related]
3. Expression of matrix metalloproiteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue, compared with the surrounding non-tumor tissue.
Matsunaga Y; Koda M; Murawaki Y
Res Commun Mol Pathol Pharmacol; 2004; 115-116():143-50. PubMed ID: 17564313
[TBL] [Abstract][Full Text] [Related]
4. Expression of matrix metalloproteinases (MMPs) in cultured hepatocellular carcinoma (HCC) cells and surgically resected HCC tissues.
Ogasawara S; Yano H; Momosaki S; Nishida N; Takemoto Y; Kojiro S; Kojiro M
Oncol Rep; 2005 Jun; 13(6):1043-8. PubMed ID: 15870919
[TBL] [Abstract][Full Text] [Related]
5. The Role of Matrix Metalloproteinases in the Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma.
Scheau C; Badarau IA; Costache R; Caruntu C; Mihai GL; Didilescu AC; Constantin C; Neagu M
Anal Cell Pathol (Amst); 2019; 2019():9423907. PubMed ID: 31886121
[TBL] [Abstract][Full Text] [Related]
6. Suppression of hepatic tumor growth and metastasis by metronomic therapy in a rat model of hepatocellular carcinoma.
Jang JW; Park ST; Kwon JH; You CR; Choi JY; Jung CK; Bae SH; Yoon SK
Exp Mol Med; 2011 May; 43(5):305-12. PubMed ID: 21483229
[TBL] [Abstract][Full Text] [Related]
7. Introduction: MMPs, ADAMs/ADAMTSs research products to achieve big dream.
Okazaki I; Nabeshima K
Anticancer Agents Med Chem; 2012 Sep; 12(7):688-706. PubMed ID: 22292751
[TBL] [Abstract][Full Text] [Related]
8. Association of E-cadherin, matrix metalloproteinases, and tissue inhibitors of metalloproteinases with the progression and metastasis of hepatocellular carcinoma.
Gao ZH; Tretiakova MS; Liu WH; Gong C; Farris PD; Hart J
Mod Pathol; 2006 Apr; 19(4):533-40. PubMed ID: 16474379
[TBL] [Abstract][Full Text] [Related]
9. Involvement of matrix metalloproteinase type-3 in hepatocyte growth factor-induced invasion of human hepatocellular carcinoma cells.
Monvoisin A; Bisson C; Si-Tayeb K; Balabaud C; Desmoulière A; Rosenbaum J
Int J Cancer; 2002 Jan; 97(2):157-62. PubMed ID: 11774258
[TBL] [Abstract][Full Text] [Related]
10. Gankyrin: a novel promising therapeutic target for hepatocellular carcinoma.
Zamani P; Matbou Riahi M; Momtazi-Borojeni AA; Jamialahmadi K
Artif Cells Nanomed Biotechnol; 2018 Nov; 46(7):1301-1313. PubMed ID: 29025272
[TBL] [Abstract][Full Text] [Related]
11. The ubiquitin-proteasome system and its potential application in hepatocellular carcinoma therapy.
Chen YJ; Wu H; Shen XZ
Cancer Lett; 2016 Sep; 379(2):245-52. PubMed ID: 26193663
[TBL] [Abstract][Full Text] [Related]
12. Chrysanthemum indicum ethanolic extract inhibits invasion of hepatocellular carcinoma via regulation of MMP/TIMP balance as therapeutic target.
Wang ZD; Huang C; Li ZF; Yang J; Li BH; Liang RR; Dai ZJ; Liu ZW
Oncol Rep; 2010 Feb; 23(2):413-21. PubMed ID: 20043102
[TBL] [Abstract][Full Text] [Related]
13. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma: The beginning of a long journey.
Cascinu S
Dig Liver Dis; 2009 Oct; 41(10):707-8. PubMed ID: 19699696
[No Abstract] [Full Text] [Related]
15. A role for matrix metalloproteinases and tumor host interaction in hepatocellular carcinomas.
McKenna GJ; Chen Y; Smith RM; Meneghetti A; Ong C; McMaster R; Scudamore CH; Chung SW
Am J Surg; 2002 May; 183(5):588-94. PubMed ID: 12034400
[TBL] [Abstract][Full Text] [Related]
16. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs.
Pez F; Lopez A; Kim M; Wands JR; Caron de Fromentel C; Merle P
J Hepatol; 2013 Nov; 59(5):1107-17. PubMed ID: 23835194
[TBL] [Abstract][Full Text] [Related]
17. Rho GDP dissociation inhibitor beta promotes cell proliferation and invasion by modulating the AKT pathway in hepatocellular carcinoma.
Fang Y; Yi J; Lizhi L; Qiucheng C
DNA Cell Biol; 2014 Nov; 33(11):781-6. PubMed ID: 25180836
[TBL] [Abstract][Full Text] [Related]
18. Implication of the Hedgehog pathway in hepatocellular carcinoma.
Della Corte CM; Viscardi G; Papaccio F; Esposito G; Martini G; Ciardiello D; Martinelli E; Ciardiello F; Morgillo F
World J Gastroenterol; 2017 Jun; 23(24):4330-4340. PubMed ID: 28706416
[TBL] [Abstract][Full Text] [Related]
19. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.
Chen J; Jin R; Zhao J; Liu J; Ying H; Yan H; Zhou S; Liang Y; Huang D; Liang X; Yu H; Lin H; Cai X
Cancer Lett; 2015 Oct; 367(1):1-11. PubMed ID: 26170167
[TBL] [Abstract][Full Text] [Related]
20. Treatment of intermediate-stage hepatocellular carcinoma.
Finn RS
Clin Adv Hematol Oncol; 2015 Aug; 13(8):501-3. PubMed ID: 26351811
[No Abstract] [Full Text] [Related]
[Next] [New Search]
